# SPECIALTY QUANTITY LIMIT PROGRAM

## YONSA (abiraterone acetate)

### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

### **II. COVERED QUANTITIES**

| Medication              | Standard Limit  | Exception Limit* | FDA-recommended dosing  |
|-------------------------|-----------------|------------------|---|
| Yonsa 125 mg<br>tablets | 120 per 30 days | 240 per 30 days  | Standard dosing: 500 mg (four 125 mg tablets) once daily  |
|                         |                 |                  | Drug interaction, coadministration with a<br>strong CYP3A4 inducer: 500 mg (four<br>125 mg tablets) twice daily |

\*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

#### **III. REFERENCES**

1. Yonsa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; May 2018.

Specialty Quantity Limit Yonsa P2018.docx

© 2018 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

